Cogent Biosciences, Inc.
COGT
$39.16
$0.180.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.75% | 32.56% | 22.73% | 22.93% | 24.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.53% | 17.39% | 20.08% | 26.63% | 26.58% |
| Operating Income | -10.53% | -17.39% | -20.08% | -26.63% | -26.58% |
| Income Before Tax | -14.58% | -24.73% | -23.37% | -24.95% | -27.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.58% | -24.73% | -23.37% | -24.95% | -27.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.58% | -24.73% | -23.37% | -24.95% | -27.54% |
| EBIT | -10.53% | -17.39% | -20.08% | -26.63% | -26.58% |
| EBITDA | -10.59% | -17.48% | -20.21% | -26.86% | -26.77% |
| EPS Basic | 8.23% | -8.06% | 99.91% | 2.76% | 0.31% |
| Normalized Basic EPS | 8.22% | -8.05% | 99.91% | 8.48% | 0.32% |
| EPS Diluted | 8.23% | -8.06% | 99.91% | 2.76% | 0.31% |
| Normalized Diluted EPS | 8.22% | -8.05% | 99.91% | 8.48% | 0.32% |
| Average Basic Shares Outstanding | 24.83% | 15.42% | 139,706.04% | 28.50% | 27.95% |
| Average Diluted Shares Outstanding | 24.83% | 15.42% | 139,706.04% | 28.50% | 27.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |